Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ghent, Belgium Clinical Trials

A listing of Ghent, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (19) clinical trials

Safety of Intranodal ECI-006 in Melanoma Patients

The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens. In Cohort 1, ECI-006 will be administered 5 times by intranodal injection in melanoma patients after resection of ...

Phase

0.0 miles

Learn More »

First-in-Human Study of EOS100850 in Patients With Cancer

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 in patients with advanced solid tumors.

Phase

0.0 miles

Learn More »

Study to Assess the Safety Tolerability Pharmacokinetic and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

The primary objective of the study is to evaluate the safety and tolerability of REGN5713-5714-5715 in healthy adult participants. The secondary objectives of the study are: In Part A and Part B, to characterize the concentration time profile of single doses of REGN5713-5714-5715 in healthy adults and to assess the ...

Phase

0.0 miles

Learn More »

PIPAC Nab-pac for Stomach Pancreas Breast and Ovarian Cancer

Over 85% of women with ovarian cancer (OC) will develop a peritoneal recurrence after initial therapy. The prognosis of patients with recurrent disease is poor, with a median survival ranging from 12 to 24 months. Most of these patients ultimately develop platinum resistant disease (PROC). Current systemic therapy results in ...

Phase

1.06 miles

Learn More »

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

This study aims at evaluating the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

Phase

1.06 miles

Learn More »

Dose Escalation Study of JNJ-64007957 a Humanized BCMA CD3 DuoBody Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The study will be conducted in 2 parts, separately for IV and SC administration: dose escalation (Part 1) and dose expansion (Part 2). It will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of JNJ-64007957 administered to adult participants with relapsed or refractory multiple myeloma. The overall safety of the ...

Phase

1.06 miles

Learn More »

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

The main objective of this trial is the safety and tolerability of 3 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). Another objective is the change ...

Phase

1.06 miles

Learn More »

Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab

This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. ...

Phase

1.06 miles

Learn More »

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

The aim of the phase Ia (dose escalation) part of this trial is to assess-> determine the Maximum Tolerated Dose (MTD) using a continuous dosing schedule A, using an intermittent Schedule B (2 weeks on, one week off in 3-week cycles) and the MTD using an intermittent Schedule C (one ...

Phase

1.06 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

1.06 miles

Learn More »